Is PT-141 (Bremelanotide) Legal in Florida?

The Federal Legal Framework: FDA Approval and Scheduling

PT-141 has a clear federal status. The FDA approved bremelanotide injection (brand name Vyleesi, 1.75 mg/0.3 mL subcutaneous auto-injector) on June 21, 2019, making it the second drug approved for HSDD in premenopausal women after flibanserin (Addyi) [1]. The approval was based on two Phase 3 randomized controlled trials, RECONNECT Studies A and B, which enrolled a combined 1,247 women and demonstrated statistically significant improvements in sexual desire and distress scores versus placebo [2].

Because bremelanotide is an FDA-approved drug, it sits in a well-defined regulatory category. It is not a DEA Schedule I or II controlled substance, so the typical state-level controlled-substance prescribing restrictions that apply to opioids or stimulants do not apply here [3].

What the FDA Approval Actually Covers

The approval covers one specific use: HSDD in premenopausal women who do not have a cardiovascular disease history that contraindicates transient blood pressure elevation [1]. The labeled dose is 1.75 mg injected subcutaneously in the abdomen or thigh 45 minutes before anticipated sexual activity, no more than once every 24 hours and no more than once per day as needed [4].

Off-label prescribing for men or for other indications (erectile dysfunction, general libido enhancement) is not FDA-approved but is legally permissible for a licensed prescriber under the practice-of-medicine doctrine, provided the physician documents medical necessity and obtains informed consent [5].

Scheduling and the DEA

Bremelanotide does not appear on any DEA schedule as of 2025 [3]. This matters practically: Florida physicians can prescribe it without a DEA Schedule II triplicate or special registration beyond a standard DEA number. Pharmacies can dispense it without the additional logging requirements tied to controlled substances.

Florida State Law and the Board of Pharmacy

Florida does not have a state statute that specifically restricts bremelanotide beyond the general framework that governs all prescription drugs. Under Florida Statute § 465 (the Pharmacy Practice Act) and Florida Statute § 458 (the Medical Practice Act), any drug requiring a prescription under federal law also requires a valid prescription in Florida [6].

A "valid prescription" under Florida law means a prescription issued by a licensed practitioner in the context of a legitimate physician-patient relationship, for a documented medical purpose [6]. The prescriber must hold an active Florida license (or a telehealth registration, discussed below).

Florida Board of Pharmacy Rules on Compounding

Compounded bremelanotide occupies a separate but equally legal track. Florida-registered 503A compounding pharmacies may compound bremelanotide for individual patients when [7]:

• A valid, patient-specific prescription exists
• The compounded preparation is not essentially a copy of an available commercial product (or there is documented clinical difference, such as a different concentration or route)
• The bulk active pharmaceutical ingredient (API) used is USP/NF grade or sourced from an FDA-registered facility

The Florida Board of Pharmacy adopted rules aligned with USP <797> sterile compounding standards, which apply to injectable bremelanotide preparations [7]. Any 503A pharmacy compounding injectable bremelanotide for Florida patients must comply with these sterile technique and beyond-use dating requirements.

503B Outsourcing Facilities

503B outsourcing facilities (federally registered under 21 U.S.C. § 353b) may also compound bremelanotide for office use without a patient-specific prescription, provided the drug is not on the FDA's Demonstrable Difficulties for Compounding list [8]. As of mid-2025, bremelanotide does not appear on that list. However, 503B facilities cannot compound a drug that is essentially a copy of a commercially available product unless there is a documented clinical difference, so the commercial availability of Vyleesi creates a compliance consideration that individual 503B facilities must evaluate [8].

The FDA Bulks List: Why It Matters for Compounding

The FDA maintains a list of bulk drug substances that may be used in compounding under section 503A (the "503A Bulks List") and a separate list of substances that are prohibited [9]. Bremelanotide is not currently on the prohibited list, and it does not appear on the affirmative 503A Bulks List either, which places it in an interpretive space: compounders relying on the FDA-approved drug status (rather than bulk-substance designation) argue it may be compounded from bulk API under existing 503A case law, while the FDA's formal position is that compounding from bulk is permissible only for substances on the affirmative list or for drugs not commercially available in a form meeting patient needs [9].

Florida pharmacists and prescribers should confirm the current status with their compounding pharmacy's regulatory counsel before initiating bulk-compounded bremelanotide, because the FDA's bulk-substance rulemaking is ongoing [9].

The practical decision tree for Florida prescribers is:

1. Brand-name Vyleesi (1.75 mg auto-injector): fully legal, dispensed by any licensed Florida pharmacy with a valid prescription. Covered by some insurance plans for HSDD.
2. 503A compounded bremelanotide (patient-specific, from FDA-registered API supplier): legal when prescription requirements and USP <797> standards are met; confirm bulk API status with pharmacy.
3. 503B outsourced preparation: legal for office dispensing when no Demonstrable Difficulties listing exists and clinical differentiation from Vyleesi is documented.
4. Research-chemical PT-141 from online vendors: not legal for human use without a prescription; purchasing for self-administration violates federal law.

How to Get a Legal PT-141 Prescription in Florida

In-Person Evaluation

Any Florida-licensed physician, nurse practitioner, or physician assistant with prescriptive authority can prescribe bremelanotide after conducting an appropriate clinical evaluation. For women with HSDD, this typically involves ruling out contributing medical or psychiatric causes, reviewing cardiovascular history (transient systolic BP increases of approximately 6 mmHg were recorded in RECONNECT trials [2]), and confirming the absence of contraindications such as uncontrolled hypertension or known cardiovascular disease.

The American College of Obstetricians and Gynecologists (ACOG) Committee Opinion 659 notes that HSDD affects an estimated 8% to 19% of premenopausal women in the United States and calls for clinician-guided pharmacologic options when behavioral interventions are insufficient [10]. A formal diagnosis supported by a validated tool such as the Female Sexual Function Index (FSFI) or the Decreased Sexual Desire Screener (DSDS) strengthens the medical record and supports the prescription's legitimacy.

Telehealth in Florida

Florida's Telehealth Act (Florida Statute § 456.47) permits out-of-state providers registered with the Florida Department of Health to practice telehealth and prescribe non-controlled medications to Florida patients [11]. Bremelanotide, as a non-scheduled drug, may be prescribed via a synchronous audio-visual telehealth visit after the provider establishes a legitimate provider-patient relationship and completes a sufficient history and review [11].

HealthRX telehealth providers evaluating Florida patients for bremelanotide follow a protocol that includes a structured sexual health intake, current medications review (particularly antihypertensives and serotonergic drugs), blood pressure history, and a cardiovascular risk screen. The FDA label explicitly contraindicates use in patients with known cardiovascular disease [4].

What to Expect at the Pharmacy

Once a valid prescription is issued, a Florida-licensed pharmacy or a registered 503A compounding pharmacy can dispense bremelanotide. Vyleesi is available as a single-use 1.75 mg/0.3 mL auto-injector at a list price of approximately $900 per dose without insurance; GoodRx and manufacturer savings programs may reduce out-of-pocket cost [12]. Compounded preparations are typically less expensive but require verification of the pharmacy's state registration and sterile compounding certification.

Clinical Profile: Efficacy and Safety Data

Understanding the clinical data is necessary for informed consent and sets realistic expectations.

Efficacy in RECONNECT

The two key RECONNECT trials enrolled 1,247 premenopausal women with HSDD and randomized them to bremelanotide 1.75 mg SC or placebo as-needed over 24 weeks [2]. The co-primary endpoints were change from baseline in the Female Sexual Function Index desire domain and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) score.

In RECONNECT Study A, the bremelanotide group showed a mean increase in FSFI desire domain score of 0.35 points over placebo (P<0.001) and a mean decrease of 4.0 points on the FSDS-DAO versus 2.2 for placebo (P<0.001) [2]. These numbers are statistically significant but modest. The FDA's approval was based on a clinically meaningful proportion of responders reporting improvement, not on large absolute score changes [1].

Safety: What Florida Patients Need to Know

The most common adverse effect in RECONNECT was nausea, reported by 40.2% of bremelanotide-treated subjects versus 12.9% on placebo [2]. Flushing occurred in 20.4% versus 3.8%, and headache in 11.4% versus 4.6% [2]. Hyperpigmentation (focal, persistent) was reported in 1% of subjects with longer-term use [4].

Blood pressure monitoring is a clinical consideration. The FDA label states that mean transient increases of approximately 6 mmHg in systolic and 3 mmHg in diastolic blood pressure can occur, peaking 12 minutes post-dose and resolving in approximately 12 hours [4]. The FDA label also warns about flushing, nausea vomiting, and the risk of hyperpigmentation with frequent use [4].

The American Heart Association's scientific statement on sexual activity and cardiovascular disease recommends baseline cardiovascular risk stratification before initiating any pharmacotherapy for sexual dysfunction, noting that stable low-risk patients can generally use approved agents safely [13].

Off-Label Use in Men: What Florida Law Says

Bremelanotide is not FDA-approved for any indication in men. Small studies suggest potential benefit in men with erectile dysfunction not fully responsive to PDE5 inhibitors. A Phase 2 trial by Diamond et al. (2004, N=40) showed that intranasal PT-141 improved erectile function scores versus placebo in men with ED [14]. The intranasal formulation was never approved; the subcutaneous form studied in women is the only approved version.

A Florida physician may legally prescribe bremelanotide off-label for men after documenting the clinical rationale, discussing the lack of FDA approval and supporting evidence, and obtaining informed consent [5]. The prescription is written on a standard prescription pad and does not require any special permit. The legal exposure for the physician is professional liability if outcomes are poor and documentation is inadequate, not criminal or pharmacy board liability for the act of off-label prescribing itself.

What Is Not Legal: Research Chemicals and Gray-Market Sources

Vendors selling "PT-141 research peptide" for purported human self-administration exist online and frequently ship to Florida addresses. This activity is not legal for human use. Under the Federal Food, Drug, and Cosmetic Act (FD&C Act) 21 U.S.C. § 331, introducing an unapproved new drug into interstate commerce for human use is prohibited [15]. The "research use only" label on these products does not create a legal exemption for personal self-injection.

The FDA has issued multiple warning letters to peptide vendors selling bremelanotide and related melanocortin agonists as research chemicals intended for human use [16]. Florida's own Department of Health can refer violations to federal authorities under its coordination role with the FDA's state program.

Risks beyond the legal exposure include unknown purity, incorrect dosing due to unlabeled concentration, non-sterile preparation causing injection-site infection, and cardiovascular events without physician oversight.

Practical Steps for Florida Residents

Getting legal access to bremelanotide in Florida takes four steps.

Step 1. Schedule a telehealth or in-person appointment with a Florida-licensed or Florida-registered telehealth provider who offers sexual health services. Provide a complete medication list and blood pressure history.

Step 2. Complete a validated HSDD screening tool (DSDS or FSFI) as part of the clinical evaluation. If HSDD is confirmed and contraindications are ruled out, the prescriber issues a prescription.

Step 3. Choose a dispensing path: brand-name Vyleesi through a retail pharmacy, or a state-registered 503A compounding pharmacy for a compounded preparation. Confirm the compounding pharmacy's Florida registration at the Florida Board of Pharmacy licensee search portal [7].

Step 4. Follow the FDA-labeled administration instructions: 1.75 mg SC, 45 minutes before activity, no more than one dose per 24 hours. Report any hypertension symptoms, persistent nausea, or skin darkening to your prescriber.

The RECONNECT trial data showed meaningful symptom response within 4 weeks of as-needed use for most responders [2]. If no response is apparent after 8 weeks of consistent use, a reassessment of diagnosis and treatment plan is warranted.